Christopher Booth
About Christopher Booth
Christopher Booth is a Financial Controller with extensive experience in finance roles across various industries, including biotech and tobacco. He has held key positions at companies such as MeiraGTx, Tideway London, and British American Tobacco, demonstrating strong technical skills in financial reporting and compliance.
Current Role at MeiraGTx
Christopher Booth serves as the Financial Controller at MeiraGTx, a position he has held since 2022. In this role, he oversees the financial reporting for all European entities, ensuring compliance with tax regulations. His work contributes to the financial integrity and operational efficiency of the organization within the biotech sector.
Previous Experience in Finance
Before joining MeiraGTx, Christopher Booth held several finance-related positions. He worked at Tideway London as Financial Controller from 2020 to 2022, and prior to that, he served as Financial Control Manager from 2016 to 2020. His experience also includes a role as Management Reporting Manager at British American Tobacco from 2012 to 2014, and as Finance Manager at Lend Lease for a brief contract in 2014.
Career Background at Deloitte and British American Tobacco
Christopher Booth began his career at Deloitte UK, where he worked as an Assistant Manager in Audit from 2005 to 2009. He later joined British American Tobacco, where he progressed from Senior Financial Accountant from 2009 to 2012 to Management Reporting Manager until 2014. His roles at these organizations provided him with a solid foundation in financial management and reporting.
Educational Background
Christopher Booth studied at The University of Manchester, where he earned a Bachelor of Science (BSc) degree in Geography from 2002 to 2005. This educational background has contributed to his analytical skills and understanding of financial systems.
Expertise in Finance and Biotech Sector
Christopher Booth possesses strong technical skills that enhance the financial control function in dynamic and innovative organizations. He has extensive experience leading high-performing finance functions within the biotech sector, specifically for a NASDAQ-listed company, demonstrating his capability in managing complex financial environments.